Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Reports Strong Revenue Growth, Slightly Smaller Loss in Q4

NEW YORK, Feb.14 - Ciphergen Biosystems reported strong growth in revenues and R&D spending during the fourth quarter of 2002 today, along with a slightly smaller net loss.


Revenues for the quarter ended Dec. 31 increased to $13.6 million, up from $7.3 million during the same period the year before.


R&D spending during the quarter was $6.1 million, up from $4.0 million during the year-ago period.


Net losses decreased slightly, from $7.1 million or $.27 per share to $6.7 million or $.25 per share.


Ciphergen said it had $42.5 million in cash, cash equivalents, and investments in securities as of Dec. 31, 2002.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.